Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology

  Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and
  Sanofi to Redefine Companion Diagnostics for Oncology

Business Wire

SAN DIEGO -- August 21, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced it has formed collaborative
partnerships with leading pharmaceutical companies to develop a universal
next-generation sequencing (NGS)-based oncology test system. The system will
be used for clinical trials of targeted cancer therapies with a goal of
developing and commercializing a multi-gene panel for therapeutic selection,
resulting in a more comprehensive tool for precision medicine. Initial
strategic partners include AstraZeneca, Janssen Biotech, Inc., and Sanofi

Illumina is working with the strategic partners to develop assays that detect
and measure multiple variants simultaneously to support partners’ clinical
trials, with the objectives of securing regulatory agency approvals and test
commercialization. In parallel, Illumina is working with key thought leaders
to set standards for NGS-based assays in routine clinical oncology practice,
as well as to define regulatory frameworks to enable this new testing
paradigm. Together, Illumina and its strategic partners aim to transition from
single-analyte companion diagnostics to panel-based assays that select for
“companion therapeutics.”

“The transition to patient-centered companion therapeutics marks a new era for
oncology, and we are pleased to see pharmaceutical companies working with
Illumina on a universal platform to bring life-saving treatments through their
development pipelines,” said Ellen V. Sigal, Ph.D., Chair and Founder of
Friends of Cancer Research. “This is the type of collaboration that will make
real progress for patients.”

Ruth March, Vice President, Personalised Healthcare & Biomarkers at
AstraZeneca, said, “This partnership has the potential to deliver an
unprecedented amount of clinical information from a single test. Illumina’s
technology will inform doctors about the molecular make-up of their patients’
tumors, enabling them to match medicines to the drivers of disease. Our aim is
that doctors can use these tests to prescribe the right drugs to the right
patients– bringing benefits to healthcare professionals, payers and patients

To date 125 known cancer driver genes have been discovered – 71 tumor
suppressors and 54 oncogenes – that drive tumor growth through 12 cellular
signaling pathways.^1 While today the number of available targeted therapies
is limited, an estimated 800 oncology drugs are in development, many of which
are designed to target specific mutations. With the emergence of new targeted
therapies, there is growing need for new companion diagnostic tests.

“Building on our experience with the MiSeqDx, the only FDA-cleared NGS
platform, as well as the additional regulatory expertise we gained with the
acquisition of Myraqa, Illumina is developing the universal test system to
support our partners’ oncology drug pipelines,” said Rick Klausner, M.D.,
Illumina’s Chief Medical Officer. “These agreements represent the deep
engagement between Illumina and the pharma community to create the technical,
clinical, regulatory and ultimately commercial solutions for the next
generation of molecular oncology. We’re excited to be working together to
maximize benefits to patients with cancer.”

For more information, visit


Illumina( is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this

^1 Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, et al. (2013)
Cancer Genome Landscapes. Science 339: 1546–1548.


Illumina, Inc.
Rebecca Chambers
Jennifer Temple
Press spacebar to pause and continue. Press esc to stop.